WO2002026730A2 - Fluorinated quinolones as antimitotic and antitumor agents - Google Patents
Fluorinated quinolones as antimitotic and antitumor agents Download PDFInfo
- Publication number
- WO2002026730A2 WO2002026730A2 PCT/US2001/029916 US0129916W WO0226730A2 WO 2002026730 A2 WO2002026730 A2 WO 2002026730A2 US 0129916 W US0129916 W US 0129916W WO 0226730 A2 WO0226730 A2 WO 0226730A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- hydroxy
- lower alkyl
- halo
- amino
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
Definitions
- the present invention concerns quinolone derivatives, pharmaceutical formulations containing the same, and methods of use thereof as antimitotic and antitumor agents, particularly for the treatment of tumors such as breast cancer and ovarian cancer.
- Microtubules are one of the most important subcellular targets for the development of anticancer chemotherapeutic compounds.
- Vinca alkaloids and taxoids are well-known examples of antimitotic agents that are widely used clinically to treat different cancers (E. Rowinsky et al., Pharmacol. & Ther. 1992, 52, 35-84; J. Verweij et al, Ann. Oncol. 1994, 5, 495-505).
- Colchicine ( Figure 1) is another well- known agent that inhibits microtubule assembly (S. Hastie, Pharm. & Ther. 1991, 57, 377-401; S. Hastie, Pharm. & Ther. 1991, 51, 377-401).
- colchicine Although colchicine has limited utility for cancer therapy, the drug has been an important tool in studies of microtubule structure and function.
- the vinca alkaloids, taxoids, and colchicine each interact with tubulin by a unique mechanism, probably involving distinct binding sites on the protein.
- an object of the present invention is to develop additional compounds that can be used as antimitotic agents, antitumor agents, or both.
- a first aspect of the present invention is, accordingly, acompound according to Formula I, or a pharmaceutically acceptable salt thereof:
- Ri is selected from the group consisting of H, hydroxy, lower alkyl, lower alkoxy, hydroxy, halo, and amino (preferably H or lower alkyl; most preferably H);
- R 2 is is selected from the group consisting of H, hydroxy, lower alkyl, lower . alkoxy, hydroxy, halo, and amino (preferably H or lower alkyl; most preferably H);
- R 3 is is selected from the group consisting of H, hydroxy, lower alkyl, lower alkoxy, hydroxy, halo, and amino (preferably H or lower alkyl; most preferably H);
- R 4 is is selected from the group consisting of H, hydroxy, lower alkyl, lower alkoxy, hydroxy, halo, and amino (preferably H or lower alkyl; most preferably H);
- R 5 is is selected from the group consisting of H, hydroxy, lower alkyl, lower alkoxy, hydroxy, halo, and amino (preferably H or lower alkyl; most preferably H); and n is 0, 1, 2, 3 or 4 (it being understood that, when n is 0, then all positions are substituted by H).
- F is substituted on the phenyl group at the ortho position, or multi-F substituted at the ortho and other positions, as in a compound of the structure:
- a second aspect of the present invention is a pharmaceutical formulation comprising or consisting essentially of a compound according to Formula I, or a pharmaceutically acceptable salt thereof, in a pharmaceutically acceptable carrier (e.g., an aqueous carrier).
- a pharmaceutically acceptable carrier e.g., an aqueous carrier
- a third aspect of the present invention is a method for treating a tumor , comprising administering to a subject in need of such treatment a treatment effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof.
- a fourth aspect of the present invention is a method of inhibiting cellular mitosis, comprising: contacting a cell with a compound of Formula I, or a pharmaceutically acceptable salt thereof, in an amount effective to inhibit cellular mitosis.
- a fifth aspect of the present invention is a compound according to Formula II, or a pharmaceutically acceptable salt thereof:
- Ri is selected from the group consisting of H, hydroxy, lower alkyl, lower alkoxy, " halo, amino, and heterocyclic rings;
- R 2 is selected from the group consisting of H, hydroxy, lower alkyl, lower alkoxy, halo, and amino (preferably H or loweralkyl; most preferably H);
- R 3 is selected from the group consisting of H, hydroxy, lower alkyl, lower alkoxy, halo, and amino (preferably H or loweralkyl; most preferably H);
- R 4 is selected from the group consisting of H, hydroxy, lower alkyl, lower alkoxy, halo, and amino (preferably H or loweralkyl; most preferably H).
- F is substituted on the phenyl group at the ortho position, or multi-F substituted on the phenyl group at the ortho and other positions, as in a compound of the structure:
- a sixth aspect of the present invention is a pharmaceutical formulation comprising or consisting essentially of a compound according to Formula II, or a pharmaceutically acceptable salt thereof, in a pharmaceutically acceptable carrier (e.g., an aqueous carrier).
- a pharmaceutically acceptable carrier e.g., an aqueous carrier.
- a seventh aspect of the present invention is a method for treating a tumor comprising administering to a subject in need of such treatment a treatment effective amount of a compound of Formula II, or a pharmaceutically acceptable salt thereof.
- An eighth aspect of the present invention is a method of inhibiting cellular mitosis, comprising: contacting a cell with a compound of Formula II, or a pharmaceutically acceptable salt thereof, in an amount effective to inhibit cellular mitosis.
- Figure 1 illustrates certain compounds of the present invention and certain compounds of the prior art.
- FIG. 2 illustrates a first scheme, Scheme 1, for making compounds of the present invention.
- FIG. 3 illustrates a second scheme, Scheme 2, for making compounds of the present invention.
- FIG. 4 illustrates a third scheme, Scheme 3, for making compounds of the present invention.
- Alkyl refers to linear or branched, saturated or unsaturated hydrocarbon chains, including for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, and tert-butyl groups.
- Alkoxy refers to linear or branched, saturated or unsaturated oxo-hydrocarbon chains, including for example mefhoxy, ethoxy, propoxy, isopropoxy, butoxy, and t-butoxy.
- Amino refers to the substiruent -NR ⁇ R 2 , where Ri and R 2 are each independently selected from the group consisting of H and C1-C4 alkyl.
- Halo refers to fluorine, chlorine, bromine, and iodine.
- Heterocyclic rings refers to any heterocyclic ring, particularly 5 or 6 member heterocyclic rings containing one or two hetero atoms selected from the group consisting of N, S, and O.
- Treat” or “treating” as used herein refers to any type of treatment that imparts a benefit to a patient afflicted with a disease, including improvement in the condition of the patient (e.g., in one or more symptoms), delay in the progression of the disease, etc.
- “Pharmaceutically acceptable” as used herein means that the compound or composition is suitable for administration to a subject to achieve the treatments described"herein, without unduly deleterious side effects in light of the severity of the disease and necessity of the treatment.
- Preparation of compounds shown in Figure 4 may be carried out by condensation of the appropriate 2-amino acetophenone and 2-fiuoro benzaldehyde, followed by acid-catalyzed cyclization to give the final products.
- the active compounds disclosed herein can, as noted above, be prepared in the form of their pharmaceutically acceptable salts.
- Pharmaceutically acceptable salts are ⁇ salts that retain the desired biological activity of the parent compound and do not impart undesired toxicological effects.
- Examples of such salts are (a) acid addition salts formed with inorganic acids, for example hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid and the like; and salts formed with organic acids such as, for example, acetic acid, oxalic acid, tartaric acid, succinic acid, maleic acid, fumaric acid, gluconic acid, citric acid, malic acid, ascorbic acid, benzoic acid, tannic acid, palmitic acid, alginic acid, polyglutamic acid, naphthalenesulfonic acid, methanesulfonic acid, p-toluenesulfonic acid, naphthalenedisulfonic acid, polygalacturonic
- the active compounds described above may be formulated for administration in a pharmaceutical carrier in accordance with known techniques. See, e.g., Remington, The Science And Practice of Pharmacy (9 th Ed. 1995).
- the active compound (including the physiologically acceptable salts thereof) is typically admixed with, inter alia, an acceptable carrier.
- the carrier must, of course, be acceptable in the sense of being compatible with any other ingredients in the formulation and must not be deleterious to the patient.
- the carrier may be a solid or a liquid, or both, and is preferably formulated with the compound as a unit-dose formulation, for example, a tablet, which may contain from 0.01 or 0.5%> to 95%> or 99% by weight of the active compound.
- One or more active compounds may be incorporated in the formulations of the invention, which may be prepared by any of the well known techniques of pharmacy consisting essentially of admixing the components, optionally including one or more accessory ingredients.
- the formulations of the invention include those suitable for oral, rectal, topical, buccal (e.g., sub-lingual), vaginal, parenteral (e.g., subcutaneous, intramuscular, intradermal, or intravenous), topical (i.e., both skin and mucosal surfaces, including airway surfaces) and transdermal administration, although the most suitable route in any given case will depend on the nature and severity of the condition being treated and on the nature of the particular active compound which is being used.
- Formulations suitable for oral administration may be presented in discrete units, such as capsules, cachets, lozenges, or tablets, each containing a predetermined amount of the active compound; as a powder or granules; as a solution or a suspension in an aqueous or non-aqueous liquid; or as an oil-in- water or water-in-oil emulsion.
- Such formulations may be prepared by any suitable method of pharmacy which includes the step of bringing into association the active Compound and a suitable carrier (which may contain one or more accessory ingredients as noted above).
- the formulations of the invention are prepared by uniformly and intimately admixing the active compound with a liquid or finely divided solid carrier, or both, and then, if necessary, shaping the resulting mixture.
- a tablet may be prepared by compressing or molding a powder or granules containing the active compound, optionally with one or more accessory ingredients.
- Compressed tablets may be prepared by compressing, in a suitable machine, the compound in a free-flowing form, such as a powder or granules optionally mixed with a binder, lubricant, inert diluent, and/or surface active/dispersing agent(s).
- Molded tablets may be made by molding, in a suitable machine, the powdered compound moistened with an inert liquid binder.
- Formulations suitable for buccal (sub-lingual) administration include lozenges comprising the active compound in a flavoured base, usually sucrose and acacia or tragacanth; and pastilles comprising the compound in an inert base such as gelatin and glycerin or sucrose and acacia.
- Formulations of the present invention suitable for parenteral administration comprise sterile aqueous and non-aqueous injection solutions of the active compound, which preparations are preferably isotonic with the blood of the intended recipient. These preparations may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient.
- Aqueous and non-aqueous sterile suspensions may include suspending agents and thickening agents.
- the formulations may be presented in unit ⁇ dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example, saline or water-for-injection immediately prior to use.
- Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.
- an injectable, stable, sterile composition comprising a compound of Formula (I), or a salt thereof, in a unit dosage form in a sealed container.
- the compound or salt is provided in the form of a lyophilizate which is capable of being reconstituted with a suitable pharmaceutically acceptable carrier to form a liquid composition suitable for injection thereof into a subject.
- the unit dosage form typically comprises from about 10 mg to about 10 grams of the compound or salt.
- emulsifying agent which is physiologically acceptable may be employed in sufficient quantity to emulsify the compound or salt in an aqueous carrier.
- emulsifying agent is phosphatidyl choline.
- Formulations suitable for rectal administration are preferably presented as unit dose suppositories. These may be prepared by admixing the active compound with one or more conventional solid carriers, for example, cocoa butter, and then shaping the resulting mixture.
- Formulations suitable for topical application to the skin preferably take the form of an ointment, cream, lotion, paste, gel, spray, aerosol, or oil. Carriers which may be used include petroleum jelly, lanoline, polyethylene glycols, alcohols, transdermal enhancers, and combinations of two or more thereof.
- Formulations suitable for transdermal administration may be presented as discrete patches adapted to remain in intimate contact with the epidermis of the recipient for a prolonged period of time. Formulations suitable for transdermal administration may also be delivered by iontophoresis (see, for example, Pharmaceutical Research 3 (6):318 (1986)) and typically take the form of an optionally buffered aqueous solution of the active compound. Suitable formulations comprise citrate or bisVtris buffer (pH 6) or ethanol/water and contain from 0.1 to 0.2M active ingredient. Further, the present mvention provides liposomal formulations of the compounds disclosed herein and salts thereof. The technology for forming liposomal suspensions is well known in the art.
- the compound or salt thereof when the compound or salt thereof is an aqueous-soluble salt, using conventional liposome technology, the same may be incorporated into lipid vesicles. In such an instance, due to the water solubility of the compound or salt, the compound or salt will be substantially entrained within the hydrophilic center or core of the liposomes.
- the lipid layer employed may be of any conventional composition and may either contain cholesterol or may be cholesterol- free.
- the salt may be substantially entrained within the hydrophobic lipid bilayer which forms the structure of the liposome. In either instance, the liposomes which are produced may be reduced in size, as through the use of standard sonication and homogenization techniques.
- liposomal formulations containing the compounds disclosed herein or salts thereof may be lyophilized to produce a lyophilizate which may be reconstituted with a pharmaceutically acceptable carrier, such as water, to regenerate a liposomal suspension.
- a pharmaceutically acceptable carrier such as water
- compositions may be prepared from the water-insoluble compounds disclosed herein, or salts thereof, such as aqueous base emulsions.
- the composition will contain a sufficient amount of pharmaceutically acceptable emulsifying agent to emulsify the desired amount of the compound or salt thereof.
- Particularly useful emulsifying agents include phosphatidyl cholines, and lecithin.
- the pharmaceutical compositions may contain other additives, such as pH-adjusting additives.
- useful pH-adjusting agents include acids, such as hydrochloric acid, bases or buffers, such as sodium lactate, sodium acetate, sodium phosphate, sodium citrate, sodium borate, or sodium gluconate.
- the compositions may contain microbial preservatives.
- Useful microbial preservatives include methylparaben, propylparaben, and benzyl alcohol. The microbial preservative is typically employed when the formulation is placed in a vial designed for multidose use.
- the pharmaceutical compositions of the present invention may be lyophilized using techniques well known in the art.
- the active compounds described herein inhibit tubulin polymerization and/or have antimitotic activity.
- Such compounds are useful for the treatment of conditions including psoriasis, gout, papiloma, warts, and various tumors, particularly solid tumors, including but not limited to lung cancer (e.g., non-small cell lung cancer), colon cancer, central nervous system cancers, melanoma, ovarian cancer, prostate cancer and breast cancer.
- Subjects to be treated by the methods of the present invention are typically human subjects although the methods of the present invention may be useful with any suitable subjects known to those skilled in the art, and particularly mammalian subjects including, in addition to humans, horses, cows, dogs, rabbits, fowl, sheep, and the like.
- the present invention provides pharmaceutical formulations comprising the compounds of Formula I, or pharmaceutically acceptable salts thereof, in pharmaceutically acceptable carriers for oral, rectal, topical, buccal, parenteral, intramuscular, intradermal, or intravenous, and transdermal administration.
- the therapeutically effective dosage of any specific compound, the use of which is in the scope of present invention will vary somewhat from compound to compound, patient to patient, and will depend upon the condition of the patient and the route of delivery.
- a dosage from about 0.1 to about 50 mg/kg will have therapeutic efficacy, with still higher dosages potentially being employed for oral and/or aerosol administration. Toxicity concerns at the higher level may restrict intravenous dosages to a lower level such as up to about 10 mg/kg, all weights being calculated based upon the weight of the active base, including the cases where a salt is employed. Typically a dosage from about 0.5 mg/kg to about 5 mg/kg will be employed for intravenous or intramuscular administration. A dosage from about 10 mg/kg to about 50 mg/kg may be employed for oral administration.
- EXAMPLE 1 EXAMPLE 1
- tubulin polymerization and [ Hjcolchicine binding assays were performed as described previously (S. Kuo et al., J. Med. Chem. 1993, 36, 1146-1156).
- polymerization assay reaction mixtures contained 10 ⁇ M tubulin, and in the colchicine binding assay, 1.0 ⁇ M- tubulin and 5.0 ⁇ M [ 3 H]colchicine.
- the cytotoxic activities of 1-7 and 13 are summarized in Table 1 and effects on tubulin-based assays in Table 2.
- the results showed that the cytotoxicity, decreased about 100-fold when the ketone form of 1 was converted to an enol ether (2-5).
- Compounds 2-5 lack both the amine H and the ketone O, the two functional moieties in the B ring, and these compounds had little or no effect on tubulin polymerization.
- Reduced cytotoxic activity was also found with 6, where only a thio- ketone moiety replaced the ketone group.
- Thioketone 6 like the enol ethers, had minimal effect on tubulin polymerization.
- a Data obtained from NCI's in vitro disease-oriented human tumor cell screen obtained from NCI's in vitro disease-oriented human tumor cell screen.
- K-562 leukemia cell line
- HCT-116 colon cancer cell line
- ONCAR-3 ovarian cancer cell line
- RXF-393 renal cancer cell line
- RXF-393 renal cancer cell line
- SF-286 and SF-295 C ⁇ S tumor cell lines.
- c Log concentrations that reduced cell growth by 50%.
- d "nt" means not tested
- a ITP inhibition of tubulin polymerization.
- b ICB inhibition of colchicine binding; evaluated only when polymerization IC 50 ⁇ 1.0 ⁇ M. ° In the colchicine binding experiments, these values refer to the inhibitor concentration used.
- the [ HJcolchicine concentration was 5 ⁇ M, and the tubulin concentration was 1 ⁇ M. T>atafromS. Kuo etal.,J. med. Chem.1993, 36, 1146-1156.6.
- f Data from Y. Xia et al., J Med. Chem.1998, 4 1155-1162.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002531114A JP2004509956A (en) | 2000-09-25 | 2001-09-25 | Fluorinated quinolones as antimitotic and antitumor agents |
CA002423482A CA2423482A1 (en) | 2000-09-25 | 2001-09-25 | Fluorinated quinolones as antimitotic and antitumor agents |
EP01977164A EP1322615A2 (en) | 2000-09-25 | 2001-09-25 | Fluorinated quinolones as antimitotic and antitumor agents |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/669,155 US6569870B1 (en) | 2000-09-25 | 2000-09-25 | Fluorinated quinolones as antimitotic and antitumor agents |
US09/669,155 | 2000-09-25 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002026730A2 true WO2002026730A2 (en) | 2002-04-04 |
WO2002026730A3 WO2002026730A3 (en) | 2002-09-19 |
Family
ID=24685280
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/029916 WO2002026730A2 (en) | 2000-09-25 | 2001-09-25 | Fluorinated quinolones as antimitotic and antitumor agents |
Country Status (6)
Country | Link |
---|---|
US (1) | US6569870B1 (en) |
EP (1) | EP1322615A2 (en) |
JP (1) | JP2004509956A (en) |
CN (1) | CN1476435A (en) |
CA (1) | CA2423482A1 (en) |
WO (1) | WO2002026730A2 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6916831B2 (en) | 2003-02-24 | 2005-07-12 | The University Of North Carolina At Chapel Hill | Flavone acetic acid analogs and methods of use thereof |
EP2096924A1 (en) * | 2006-12-07 | 2009-09-09 | China Medical University | Novel hydrophilic derivatives of 2-aryl-4-quinolones as anticancer agents |
WO2009087684A3 (en) * | 2008-01-04 | 2010-11-04 | Panjab University | Novel tetrahydroquinolines as aromatase inhibitors |
WO2012009519A1 (en) * | 2010-07-15 | 2012-01-19 | Efficient Pharma Management Corp. | Synthesis and anticancer activity of aryl and heteroaryl-quinolin derivatives |
US11820747B2 (en) | 2021-11-02 | 2023-11-21 | Flare Therapeutics Inc. | PPARG inverse agonists and uses thereof |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100488960C (en) * | 2006-03-09 | 2009-05-20 | 中国药科大学 | 2-substituted quinolone compound and use in pharmacy |
CN102675200B (en) * | 2012-05-16 | 2014-04-09 | 中国药科大学 | 2-phenyl-4-carbostyril compounds with antineoplastic activity, and preparation method and usage thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996010563A1 (en) * | 1994-09-30 | 1996-04-11 | The University Of North Carolina At Chapel Hill | 2-aryl-4-quinolones as antitumor compounds |
-
2000
- 2000-09-25 US US09/669,155 patent/US6569870B1/en not_active Expired - Fee Related
-
2001
- 2001-09-25 JP JP2002531114A patent/JP2004509956A/en active Pending
- 2001-09-25 CN CNA018192165A patent/CN1476435A/en active Pending
- 2001-09-25 WO PCT/US2001/029916 patent/WO2002026730A2/en not_active Application Discontinuation
- 2001-09-25 CA CA002423482A patent/CA2423482A1/en not_active Abandoned
- 2001-09-25 EP EP01977164A patent/EP1322615A2/en not_active Withdrawn
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996010563A1 (en) * | 1994-09-30 | 1996-04-11 | The University Of North Carolina At Chapel Hill | 2-aryl-4-quinolones as antitumor compounds |
Non-Patent Citations (3)
Title |
---|
DATABASE CA [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; KAYE, PERRY T. ET AL: "Mass spectrometric analysis of 2-phenyl-1,2,3,4-tetrahydro-1,4- benzodiazepin-5-ones and their tetrazolo[1,5-d] derivatives" retrieved from STN Database accession no. 121:9280 XP002201148 & J. CHEM. RES., SYNOP. (1994), (2), 62-3,367-82 , * |
XIA, YI ET AL: "Antitumor Agents. 211. Fluorinated 2-Phenyl-4-quinolone Derivatives as Antimitotic Antitumor Agents" JOURNAL OF MEDICINAL CHEMISTRY (2001), 44(23), 3932-3936 , XP002201147 * |
ZHANG S-X ET AL: "Antitumor Agents. 199. Three-Dimensional Quantitative Structure-Activity Relationship Study of the Colchicine Binding Site Ligands Using Comparative Molecular Field Analysis" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 43, no. 2, 2000, pages 167-176, XP002170701 ISSN: 0022-2623 * |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6916831B2 (en) | 2003-02-24 | 2005-07-12 | The University Of North Carolina At Chapel Hill | Flavone acetic acid analogs and methods of use thereof |
TWI414293B (en) * | 2006-12-07 | 2013-11-11 | Univ China Medical | Novel hydrophilic derivatives of 2-aryl-4-quinolones as anticancer agents |
EP2096924A4 (en) * | 2006-12-07 | 2010-09-15 | Univ China Medical | Novel hydrophilic derivatives of 2-aryl-4-quinolones as anticancer agents |
EP2455369A1 (en) * | 2006-12-07 | 2012-05-23 | China Medical University | Derivatives of 2-aryl-4-quinolones having an aminoalkyl group as anticancer agents |
EP2468747A1 (en) * | 2006-12-07 | 2012-06-27 | China Medical University | 2-Selenophene-4-quinolones as anticancer agents |
US8440692B2 (en) | 2006-12-07 | 2013-05-14 | China Medical University | Hydrophilic derivatives of 2-aryl-4-quinolones as anticancer agents |
EP2096924A1 (en) * | 2006-12-07 | 2009-09-09 | China Medical University | Novel hydrophilic derivatives of 2-aryl-4-quinolones as anticancer agents |
US9023866B2 (en) | 2006-12-07 | 2015-05-05 | China Medical University | 2-selenophene-4-quinolones as anticancer agents |
WO2009087684A3 (en) * | 2008-01-04 | 2010-11-04 | Panjab University | Novel tetrahydroquinolines as aromatase inhibitors |
WO2012009519A1 (en) * | 2010-07-15 | 2012-01-19 | Efficient Pharma Management Corp. | Synthesis and anticancer activity of aryl and heteroaryl-quinolin derivatives |
US8524740B2 (en) | 2010-07-15 | 2013-09-03 | Tairx, Inc. | Synthesis and anticancer activity of aryl and heteroaryl-quinolin derivatives |
RU2584688C2 (en) * | 2010-07-15 | 2016-05-20 | Тэйркс, Инк. | Synthesis and anticancer activity of derivatives of aryl and heteroaryl quinolines |
EP3112348A1 (en) * | 2010-07-15 | 2017-01-04 | Tairx, Inc. | Synthesis and anticancer activity of aryl and heteroaryl-quinolin derivatives |
US11820747B2 (en) | 2021-11-02 | 2023-11-21 | Flare Therapeutics Inc. | PPARG inverse agonists and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
EP1322615A2 (en) | 2003-07-02 |
JP2004509956A (en) | 2004-04-02 |
CA2423482A1 (en) | 2002-04-04 |
US6569870B1 (en) | 2003-05-27 |
WO2002026730A3 (en) | 2002-09-19 |
CN1476435A (en) | 2004-02-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6242457B1 (en) | Camptothecin derivatives having antitumor activity | |
US5731316A (en) | Derivatives of camptothecin and methods of treating cancer using these derivatives | |
US20050171138A1 (en) | Flavone acetic acid analogs and methods of use thereof | |
US20110275643A1 (en) | Aroylquinoline compounds | |
US9023866B2 (en) | 2-selenophene-4-quinolones as anticancer agents | |
US6229016B1 (en) | Method for treating tumors using 2-aryl-naphthyridin-4-ones | |
US6569870B1 (en) | Fluorinated quinolones as antimitotic and antitumor agents | |
US6624317B1 (en) | Taxoid conjugates as antimitotic and antitumor agents | |
US6034243A (en) | Intermediates in the synthesis of (±)-camptothecin and related compounds and synthesis thereof | |
EP2112154B1 (en) | Esters in position 20 of camptothecins | |
US8188089B2 (en) | Tylophorine analogs as antitumor agents | |
KR20020084082A (en) | 10,11-difluoromethylenedioxycamptothecin compounds with topoisomerase i inhibition | |
US6174918B1 (en) | Naphthoquinone antitumor compound and method | |
WO1996010563A1 (en) | 2-aryl-4-quinolones as antitumor compounds | |
US7105492B2 (en) | Camptothecin derivatives having antitumor activity | |
WO2009140467A1 (en) | Oxobenzindolizinoquinolines and uses thereof | |
EP1561753A2 (en) | Benzo[b]chromenonapthyridin-7-one and pyrano[2',3':7,8]quino[2,3-b]Quinoxalin-7-one derivatives, process of synthesis, pharmaceutical compositions and their antitumoral properties for the treatment of cancer | |
WO2014018953A1 (en) | Inauhzin analogues that induce p53, inhibit cell growth, and have antitumor activity | |
RU2803116C2 (en) | Quinolinil-containing compound, its pharmaceutical composition and use | |
WO2010102219A1 (en) | Methylenedioxybenzo [i] phenanthridine derivatives used to treat cancer | |
JP2000290280A (en) | Phenylazole compound, its production, and antihyperlipemic agent | |
Fur et al. | Optimized and convergent synthesis of potent anti-malarial aminoquinoline compounds: easy access to analogs | |
PL237866B1 (en) | Acetylene derivatives of sulfamoylquinoline with antitumour effects, method for producing and pharmaceutical composition containing them |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): CA CN JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): CA CN JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2423482 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002531114 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001977164 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 018192165 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2001977164 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001977164 Country of ref document: EP |